Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001104659-25-105834
Chunk: 8

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 8
---
 22 23 338 338 24 25e 26e 27f 28f 29f 30f - 242 +2% Q4’24 price: ~$35 (basis for Alcon offer of $55/share) Q2’25 price: ~$17 (basis for Alcon $28/share offer) Illustrative forecast @ 7% 3

6 … and the market correctly re - valued the company with minimal volatility in the 90 days preceding Alcon’s offer 1 $0.00 $10.00 $20.00 $30.00 $40.00 $50.00 $60.00 Media outlets publish articles indicating potential Alcon acquisition of STAAR STAAR highlights “softened” macroeconomic environment, especially in China 3 STAAR discloses elevated China inventory and limited expected revenue from China in 1H ‘25 3 Alcon and STAAR announce proposed merger at $28 / share in cash 2024 2025 1 3 4 1 1 v 1 2 v 3 4 2 Median price target post Q1’25 earnings: ~$19 / share Alcon offer 1. Alcon estimates 2. S&P CapitalIQ 3. STAAR Earnings Calls, Q3 2024 and Q4 2024 STAAR Stock Price 2 $ /share

7 China growth projections have corrected to reflect an underlying reality that’s dramatically lower than previously forecasted 107 148 186 2021 22 23 24e 25e 26e ~ 205 ~ 246 ~ 295 +17% 107 148 186 161 91 160 2021 22 23 24 25e 26e - 5% 1. STAAR Press Release, dated Feb 26, 2024, titled STAAR Surgical Reports 4 th Quarter and Fiscal Year 2023 Results 2. STAAR Investor Presentation, March 2024; 2024 based on 10% China sales growth guidance and ~20% estimate for 2025 and 2026 3. STAAR Management Presentation: Alcon Merger Maximizes Value for Stockholders of STAAR Surgical – September 2025 Inventory buildup Inventory bleed down Prior Guidance China ICL sales | Q1 2024 1,2 , $m Current Guidance China ICL Sales | Q3 2025 3 , $